StoxDivi's Laboratories vs Apollo Hospitals Enterprise: share price & financials comparison
NSE: DIVISLAB vs APOLLOHOSP · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Divi's Laboratories vs Apollo Hospitals Enterprise at a glance
Divi's Laboratories (DIVISLAB) has a market capitalisation of ₹2,73,493 Cr, against ₹1,21,453 Cr for Apollo Hospitals Enterprise (APOLLOHOSP). Over the past year Divi's Laboratories has returned +58.5%, compared with +7.5% for Apollo Hospitals Enterprise. On valuation, Apollo Hospitals Enterprise trades at a lower P/E of 54.2 versus 93.5. Apollo Hospitals Enterprise earns a higher return on equity (21.1% vs 17.5%). Divi's Laboratories comes out ahead on size, profitability, growth, momentum and technicals. Apollo Hospitals Enterprise comes out ahead on valuation. Across the scored metrics below, Divi's Laboratories leads on 13 and Apollo Hospitals Enterprise on 4. On StoxGud's 10-point checklist, Divi's Laboratories scores 8/10 and Apollo Hospitals Enterprise scores 8/10.
| Metric | Divi's Laboratories | Apollo Hospitals Enterprise |
|---|---|---|
| Size | ||
| Market cap | ₹2,73,493 Cr | ₹1,21,453 Cr |
| Revenue (latest FY) | ₹10,560 Cr | ₹25,228 Cr |
| Net profit (latest FY) | ₹2,568 Cr | ₹1,942 Cr |
| Valuation | ||
| P/E | 93.5 | 54.2 |
| P/B | 16.32 | 11.45 |
| Dividend yield | 0.29% | 0.24% |
| Profitability | ||
| Return on equity | 17.5% | 21.1% |
| Net profit margin | 26.0% | 8.1% |
| Operating margin | 35.3% | 15.4% |
| Growth | ||
| Revenue growth (YoY) | +27.8% | +20.8% |
| Net profit growth (YoY) | +65.5% | +32.0% |
| Revenue CAGR (multi-year) | +11.8% | +19.0% |
| Financial health | ||
| Debt to equity | 0.00 | 0.53 |
| Momentum | ||
| 1-month return | +7.6% | +6.7% |
| 1-year return | +58.5% | +7.5% |
| 3-year CAGR | +43.3% | +17.8% |
| 5-year CAGR | +16.1% | +13.9% |
| 10-year CAGR | +23.3% | +20.8% |
| Distance from 52W high | +0.0% | -6.9% |
| Technicals | ||
| RSI (14) | 82 | 66 |
| Price vs 200-day avg | +39.4% | +3.9% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Divi's Laboratories | Apollo Hospitals Enterprise |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✗ |
| P/E below industry median | ✗ | ✗ |
| Score | 8/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Divi's Laboratories or Apollo Hospitals Enterprise?
Divi's Laboratories has a market cap of ₹2,73,493 Cr and Apollo Hospitals Enterprise has a market cap of ₹1,21,453 Cr as of 06 Nov 2026.
Which has a lower P/E, Divi's Laboratories or Apollo Hospitals Enterprise?
Apollo Hospitals Enterprise has the lower P/E: Divi's Laboratories trades at 93.5 and Apollo Hospitals Enterprise at 54.2.
Which gave better returns in the last year, Divi's Laboratories or Apollo Hospitals Enterprise?
Divi's Laboratories did better: Divi's Laboratories returned +58.5% and Apollo Hospitals Enterprise returned +7.5% over one year.
Is Divi's Laboratories or Apollo Hospitals Enterprise a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Divi's Laboratories scores 8/10 and Apollo Hospitals Enterprise scores 8/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.